TECH · 10-Q/A · 2026Q3 · Full report
Capital Expenditure Program
BIO-TECHNE Corp · 2026-11-12 · Importance 59 · Surprise 32 · In source text
Capital expenditures for fixed assets were $5.9 million in the first quarter of fiscal 2027, compared with $5.4 million in the first quarter of fiscal 2026. The Company expected approximately $28 million of additional capital expenditures for the remainder of fiscal 2027. Planned additions are intended to increase capacity to meet expected sales growth and are expected to be funded from available funds and operating cash flow.
Key facts
- Bio-Techne expects approximately $28 million of capital expenditures for the remainder of fiscal 2027, financed through available funds and operating cash flow; additions are intended to increase capacity for expected sales growth. source
- BIO-TECHNE's additions to property and equipment were $5.917 million for the quarter ended September 30, 2026. source
- Capital expenditures for fixed assets were $5.9 million in the first quarter of fiscal 2027 and $5.4 million in the first quarter of fiscal 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | -0.9% | Bio-Techne expects approximately $28 million of capital expenditures for the remainder of fiscal 2027, financed through available funds… |
| assets | positive | committed | +0.9% | Bio-Techne expects approximately $28 million of capital expenditures for the remainder of fiscal 2027, financed through available funds… |